title: A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.
abstract: OBJECTIVE
  Patients who have hormone receptor-positive breast cancer and who are taking aromatase inhibitors (AIs) should understand the benefits and risks of concomitant dietary supplement (DS) use. The International Society for Integrative Oncology (SIO) encourages patients to discuss DS use with their health care practitioners. The objective was to conduct a pilot study rating Internet websites from the perspective of health care practitioners for information about AI-DS interactions.
  
  
  METHODS
  Five (5) Internet websites suggested by SIO were evaluated using the DISCERN instrument rating tool. The available AI-DS information on these websites was rated by 4 evaluators: 2 naturopathic doctors, 1 oncology pharmacy resident, and a pharmacy student.
  
  
  RESULTS
  The overall rankings ranged from 1.6 to 3.9, with considerable variability in the type of information available from the websites. The interevaluator rankings of the websites ranged from 0.44 to 0.89. The evaluators consistently found the most reliable, unbiased, and comprehensive information on AI-DS interactions at the Natural Medicines Comprehensive Database and Memorial Sloan-Kettering Cancer Center websites. However, more than one database was needed for provision of optimal patient information on AI-DS interactions.
  
  
  CONCLUSIONS
  In order to effectively advise patients regarding AI-DS interactions, more than one website should be evaluated to assess the potential efficacy and safety of DS in women whose breast cancer is being treated with an AI.
authors.affiliation: University of Washington School of Pharmacy, Seattle, WA 98195, USA.
authors.forename: Cara L
authors.initials: CL
authors.lastname: McDermott
authors.forename: Angela A
authors.initials: AA
authors.lastname: Hsieh
authors.forename: Erin S
authors.initials: ES
authors.lastname: Sweet
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Tippens
authors.forename: Jeannine S
authors.initials: JS
authors.lastname: McCune
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D001943:Breast Neoplasms / Q000188:drug therapy*; D019587:Dietary Supplements; D004347:Drug Interactions; D005260:Female; D006801:Humans; D020407:Internet; D009324:Naturopathy; D010353:Patient Education as Topic / Q000592:standards*; D010595:Pharmacists; D010865:Pilot Projects; D011960:Receptors, Estrogen; D013339:Students, Pharmacy
chemical_list: D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen
references.citation: Br J Cancer. 2004 Jan 26;90(2):408-13
references.pmid: 14735185
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4418-24
references.pmid: 15514384
references.citation: Support Care Cancer. 2004 Jun;12(6):454-62
references.pmid: 14991387
references.citation: J Soc Integr Oncol. 2007 Spring;5(2):65-84
references.pmid: 17511932
references.citation: J Clin Oncol. 2008 Feb 1;26(4):665-73
references.pmid: 18235127
references.citation: Ann Intern Med. 2002 Dec 3;137(11):889-903
references.pmid: 12458989
references.citation: Breast Cancer Res Treat. 2009 Mar;114(2):377-84
references.pmid: 18427979
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1948-55
references.pmid: 18332475
references.citation: J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):168-72
references.pmid: 17587567
references.citation: Am J Surg. 2003 May;185(5):411-5
references.pmid: 12727558
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3120-1
references.pmid: 18474872
references.citation: Clin J Oncol Nurs. 2008 Feb;12(1):33-5
references.pmid: 18258572
references.citation: Altern Ther Health Med. 2008 May-Jun;14(3):36-40
references.pmid: 18517104
references.citation: J Epidemiol Community Health. 1999 Feb;53(2):105-11
references.pmid: 10396471
references.citation: Endocr Relat Cancer. 2001 Jun;8(2):129-34
references.pmid: 11397668
references.citation: Cancer Res. 2005 Feb 1;65(3):879-86
references.pmid: 15705886
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2489-503
references.pmid: 15197212
references.citation: Pharm World Sci. 2010 Apr;32(2):179-86
references.pmid: 20077138
references.citation: Hematol Oncol Clin North Am. 2008 Aug;22(4):619-30, vii
references.pmid: 18638691
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3797-9
references.pmid: 17761968
references.citation: J Oncol Pharm Pract. 2008 Sep;14(3):123-30
references.pmid: 18719067
references.citation: Support Care Cancer. 2005 Nov;13(11):912-9
references.pmid: 15856334
references.citation: Clin Biochem. 2009 Jan;42(1-2):83-90
references.pmid: 18996104
references.citation: Oncology (Williston Park). 2003 Feb;17(2):271-7; discussion 281-2, 286-8
references.pmid: 12632867
references.citation: Crit Rev Oncol Hematol. 2009 Jan;69(1):73-82
references.pmid: 18757208
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1051-7
references.pmid: 18309940
references.citation: J Altern Complement Med. 2010 Feb;16(2):183-6
references.pmid: 20180691
references.citation: J Soc Integr Oncol. 2007 Summer;5(3):113-7
references.pmid: 17761130
references.citation: Drugs. 2009;69(13):1777-98
references.pmid: 19719333
references.citation: Breast Cancer Res Treat. 2008 Jan;107(2):167-80
references.pmid: 17876703
references.citation: J Clin Oncol. 2004 Feb 15;22(4):671-7
references.pmid: 14966090
references.citation: J Soc Integr Oncol. 2009 Summer;7(3):85-120
references.pmid: 19706235